Senzime appointed to CEBR’s "hotlist"
Uppsala, March 18, 2016. Senzime has been appointed one of ten leading medical technology companies by the CEBR - Council for European bioregions. The appointment is a further proof of Senzime’s technologies within the important and large commercial area in measurement of glucose and lactate which is critical to quickly detect complications after operations and control for treatments."The appointment of the CEBR is very pleasing and yet another step towards our commercial breakthrough. We have managed to convey what we can and will do in the strong international competition. We have the